NEMLUVIO (nemolizumab-ilto) prior authorization for atopic dermatitis
Customize your policy alerts
Sign up for all Mississippi Division of Medicaid policy alerts
Know when Mississippi Division of Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements, initial and re-authorization criteria, dosing, and formulation for NEMLUVIO for treatment of moderate-to-severe atopic dermatitis (and prurigo nodularis indication noted) for Mississippi Division of Medicaid members.
No material clinical or coverage changes in this revision.
Coverage Criteria for NEMLUVIO (nemolizumab-ilto)
inv-01: Initial Authorization
Covered when ALL of the following are met
These topical therapy trials are required unless a documented contraindication is provided.
inv-02: Re-Authorization
Continued coverage when ALL of the following are met
Re-authorization period: 1 year.
The policy does not list any indications for NEMLUVIO (nemolizumab-ilto) beyond the FDA-approved uses. NEMLUVIO is indicated for treatment of adults with prurigo nodularis and for treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. There are no explicit exclusions in this document for off‑label or other uses beyond those FDA‑approved indications noted.
Initial Therapy and Dosing
inv-11: Initial Therapy and Dosing
Dosing and initial authorization duration
Formulation: single‑dose, prefilled, dual‑chamber 30 mg pen requiring reconstitution prior to administration.
Continuation / Re-Authorization Requirements
inv-12: Re-Authorization
Re-authorization requires continued benefit and adherence to dosing limits.
Re-authorization granted for 1 year.
Provider Actions and Documentation Requirements
Prior authorization required for NEMLUVIO
Prior authorization is required for NEMLUVIO (nemolizumab-ilto). Approval will be considered only when all listed criteria are met, including minimum age per FDA label, diagnosis of moderate-to-severe chronic atopic dermatitis with ≥10% BSA, prescriber specialty or consultation, completion of required prior therapy trials, and prescribed dose within FDA-approved dosing limits.
Step therapy — biologic failure requirement
Prior authorization requires documented inadequate response after a 2-month trial of each agent to at least two of the biologics ADBRY, DUPIXENT, and EBGLYSS before approval will be granted.
- Step therapy duration: 2 months per biologic agent
- Failure criterion: inadequate response to each agent
Required supporting documentation for PA
Submit the Universal PA Form plus supporting clinical documentation demonstrating the diagnosis, extent of BSA involvement, prior topical and systemic therapy trials, specialist involvement or consultation, and documentation of inadequate responses to prior therapies.
- Diagnosis of moderate-to-severe chronic atopic dermatitis with ≥10% BSA
- Records of topical therapy trials (duration and inadequate response)
- Records of biologic trials and inadequate response (2-month trials)
- Documentation of prescriber specialty or consultation
- Prescribed dose and confirmation it does not exceed FDA dosing
Therapy and prescriber prerequisites — documentation required or risk of denial
Providers must document required prior topical therapy trials and involve an appropriate specialist; failure to document these prerequisites or absence of specialist prescribing/consultation may result in denial.
- Topical requirement: ≥2 weeks trial with inadequate response to a preferred medium to very‑high potency topical corticosteroid within the past 90 days
- Plus (for moderate AD): ≥4 weeks trial with inadequate response to a preferred topical calcineurin inhibitor or crisaborole within the past 90 days
- Plus (for severe AD): ≥4 weeks trial with inadequate response to a preferred topical calcineurin inhibitor within the past 90 days
- Prescribed by, or in consultation with, a dermatologist, allergist/immunologist, or other AD specialist
Clinical Measurements and Coding-related Values
Step Therapy Requirements
| Step | Requirement | Duration / Notes |
|---|---|---|
| 1 | Patient must have had an inadequate response after a 2-month trial of each agent to at least two of: ADBRY (tralokinumab), DUPIXENT (dupilumab), and EBGLYSS (lebrikizumab). | 2-month trial of each specified biologic required; inadequate response must be documented. |
| 2 | Prior topical therapy requirement must be met (at least 2 weeks trial with inadequate response to a preferred medium to very‑high potency topical corticosteroid within past 90 days AND at least 4 weeks trial with inadequate response to a preferred topical calcineurin inhibitor or crisaborole within past 90 days for moderate AD; for severe AD the topical calcineurin inhibitor trial applies). | Topical trials must be within the past 90 days; timelines and agents per disease severity as specified. |
| 3 | Prescribed by or in consultation with a dermatologist, allergist/immunologist, or other AD specialist; patient meets minimum FDA age for the indication and has ≥10% BSA involvement. | Age must meet package insert; BSA ≥10% required for coverage of moderate‑to‑severe AD. |
Background
NEMLUVIO (nemolizumab-ilto) is an interleukin-31 receptor antagonist approved for prurigo nodularis (adults) and for moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years and older. For atopic dermatitis the policy specifies use in combination with topical corticosteroids and/or topical calcineurin inhibitors when topical prescription therapies are inadequate. Prior authorization is required; approval considerations include diagnosis, age, documented trials of specified topical therapies and biologic agents, prescriber specialty or consultation, and dosing consistent with FDA limits. Initial authorization is set to 6 months with continuation criteria requiring demonstrated clinical benefit and adherence to dosing limits (re-authorization period 1 year). Dosing for AD per the policy: initial 60 mg (two 30 mg injections) followed by 30 mg every 4 weeks, with the option to reduce to 30 mg every 8 weeks after 16 weeks if the patient achieves clear or almost clear skin; formulation is a single-dose, prefilled, dual-chamber 30 mg pen requiring reconstitution prior to administration.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.